Long-term carvedilol therapy in patients with stage II arterial hypertension

Abstract

In total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid profile were assessed at baseline and after treatment, by conjunctival biomicroscopy and laboratory tests. Carvedilol corrected microcirculation due to its effects on vessels and capillaries, long-term carvedilol treatment didn't affected blood lipid profile, and beneficially influenced hemorheology

Keywords

• carvedilol
• arterial hypertension
• microcirculation
• blood lipid profile
• hemorheology